Novo Nordisk's CEO, who led its boom driven by obesity and diabetes medications only to see that success stall, is stepping ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ... more breakdowns on specific patient populations next month at ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

A Rutgers institute celebrates 11 honorees using business for social good at its inaugural Corporate Social Innovation ...

Novo Nordisk said this morning that it will work ... The companies said they’ll start with four development programs for potential small molecule treatments directed at targets within a class ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy ... recently released programs that cut costs to about $500 per ...

For instance, Novo Nordisk’s Rare Disease group ... a commercial enhancement program helping the company to launch medicines faster and with more impact; and a number of acquisitions that ...